<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454868</url>
  </required_header>
  <id_info>
    <org_study_id>UBrasilia</org_study_id>
    <nct_id>NCT02454868</nct_id>
  </id_info>
  <brief_title>Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade</brief_title>
  <official_title>Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brasilia University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Brasilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brasilia University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: remifentanil's optimal dose for children intubation without neuromuscular&#xD;
      blockade is unknown. Method: phase IV adaptative trial using Dixon's up-and-down method for&#xD;
      modeling remifentanil's dose-response curve for adequate intubation conditions as defined by&#xD;
      previous studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: remifentanil's optimal dose for children intubation without neuromuscular&#xD;
      blockade is unknown.&#xD;
&#xD;
      Method: phase IV adaptative trial using Dixon's up-and-down method for modeling&#xD;
      remifentanil's dose-response curve for adequate intubation conditions as defined by previous&#xD;
      studies. Remifentanil doses starting from 2mg/kg will be infused before intubation. When a&#xD;
      success occurs next patient's dose will be decreased by 0.25mg/kg/h. When a success does not&#xD;
      occur the next patient's dose will be increased by 0.25mg/kg/h. Intubation will be considered&#xD;
      adequate if patient does not cough, does not move, if vocal cords are open, if larigocsocpic&#xD;
      Cormack grade I or II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adequate intubation condition (dichotomic) as an assessment of success rate</measure>
    <time_frame>intraoperative</time_frame>
    <description>Intubation is adequate if patient does not cough, does not try to breathe, vocal cords do not move, patient does not react and laringoscopy is Cormack class I or II</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Underdosing of Unspecified General Anesthetics</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil for intubation without neuromuscular blockade</description>
    <arm_group_label>Study arm</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I or II&#xD;
&#xD;
          -  Scheduled for surgery under general anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Predicted difficult airway&#xD;
&#xD;
          -  Severe neurologic or cardiologic conditions&#xD;
&#xD;
          -  Recent upper airway infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catia S Goveia, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Brasilia</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brasilia University Hospital</investigator_affiliation>
    <investigator_full_name>Gabriel Magalhaes Nunes Guimaraes</investigator_full_name>
    <investigator_title>MSc</investigator_title>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Intubation</keyword>
  <keyword>Children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

